Open Access
Oncotarget, volume 9, issue 45, pages 27773-27788
Activating HER3 mutations in breast cancer
MISHRA ROSALIN
1
,
Alanazi Samar
1
,
Yuan Long
1
,
Solomon Thomas C.
1
,
Thaker Tarjani M.
2
,
Jura Natalia
2
,
Garrett Joan T.
1
1
James L. Winkle College of Pharmacy, University of Ohio, Cincinnati, Ohio, USA
|
2
Department of Cellular and Molecular Pharmacology, Cardiovascular Research Institute, University of California, San Francisco, California, USA
|
Publication type: Journal Article
Publication date: 2018-06-11
PubMed ID:
29963236
Oncology
Abstract
Recent studies have highlighted a role of HER3 in ER and HER2-driven breast cancers. We sought to investigate the role of patient-derived HER3 mutations in ER+ and HER2+ breast cancer cells using ectopic expression of HER3 mutants. We found that HER3T355I mutant is activating with increased cell proliferation in ER+ T47D and MCF-7 breast cancer cells lacking HER2 over-expression. Immunoblotting and receptor tyrosine kinase array results indicated that T47D and MCF-7 cells expressing HER3T355I had increased p-HER4 and p-HER1 expression. Our data showed that HER3T355I induced cell proliferation is via HER4/HER1-dependent ERK1/2 and cyclinD1 mediated pathways in ER+ cells. ERα expression is upregulated in ER+ cells expressing HER3T355I mutant. We noted crosstalk between ERα and HER3 in T47D cells. Several HER3 mutants (F94L, G284R, D297Y, T355I, and E1261A) acquired a gain-of-function phenotype in MCF10AHER2 cells and were resistant to lapatinib. These mutants increased HER2-HER3 heterodimerization. Knocking down HER3 from ovarian and colorectal cancers with endogenous HER3 mutations abrogated cancer cell proliferation. Overall, this study provides the first systematic assessment of how mutations in HER3 affect response of ER+ and HER2+ breast cancers to clinically relevant inhibitors and finds that HER3 mutations can be activating independent of HER2 over-expression.
Citations by journals
|
1
2
|
|
|
Cancers
|
Cancers
2 publications, 8.7%
|
|
PLoS ONE
|
PLoS ONE
2 publications, 8.7%
|
|
Russian Chemical Bulletin
|
Russian Chemical Bulletin
1 publication, 4.35%
|
|
Frontiers in Oncology
|
Frontiers in Oncology
1 publication, 4.35%
|
|
Cancer Chemotherapy and Pharmacology
|
Cancer Chemotherapy and Pharmacology
1 publication, 4.35%
|
|
Journal of Experimental and Clinical Cancer Research
|
Journal of Experimental and Clinical Cancer Research
1 publication, 4.35%
|
|
Nature Reviews Drug Discovery
|
Nature Reviews Drug Discovery
1 publication, 4.35%
|
|
Oncogene
|
Oncogene
1 publication, 4.35%
|
|
Molecular Biology Reports
|
Molecular Biology Reports
1 publication, 4.35%
|
|
Cytokine and Growth Factor Reviews
|
Cytokine and Growth Factor Reviews
1 publication, 4.35%
|
|
Pharmacology and Therapeutics
|
Pharmacology and Therapeutics
1 publication, 4.35%
|
|
Toxicon
|
Toxicon
1 publication, 4.35%
|
|
Cellular and Molecular Gastroenterology and Hepatology
|
Cellular and Molecular Gastroenterology and Hepatology
1 publication, 4.35%
|
|
International Journal of Biological Macromolecules
|
International Journal of Biological Macromolecules
1 publication, 4.35%
|
|
Polymers for Advanced Technologies
|
Polymers for Advanced Technologies
1 publication, 4.35%
|
|
Expert Review of Anticancer Therapy
|
Expert Review of Anticancer Therapy
1 publication, 4.35%
|
|
Polycyclic Aromatic Compounds
|
Polycyclic Aromatic Compounds
1 publication, 4.35%
|
|
Clinical Cancer Research
|
Clinical Cancer Research
1 publication, 4.35%
|
|
MedComm – Oncology
|
MedComm – Oncology
1 publication, 4.35%
|
|
Clinical Genetics
|
Clinical Genetics
1 publication, 4.35%
|
|
Cancer Reports
|
Cancer Reports
1 publication, 4.35%
|
|
1
2
|
Citations by publishers
|
1
2
3
4
5
6
|
|
|
Springer Nature
|
Springer Nature
6 publications, 26.09%
|
|
Elsevier
|
Elsevier
5 publications, 21.74%
|
|
Wiley
|
Wiley
4 publications, 17.39%
|
|
Multidisciplinary Digital Publishing Institute (MDPI)
|
Multidisciplinary Digital Publishing Institute (MDPI)
2 publications, 8.7%
|
|
Public Library of Science (PLoS)
|
Public Library of Science (PLoS)
2 publications, 8.7%
|
|
Taylor & Francis
|
Taylor & Francis
2 publications, 8.7%
|
|
Frontiers Media S.A.
|
Frontiers Media S.A.
1 publication, 4.35%
|
|
American Association for Cancer Research (AACR)
|
American Association for Cancer Research (AACR)
1 publication, 4.35%
|
|
1
2
3
4
5
6
|
- We do not take into account publications that without a DOI.
- Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
- Statistics recalculated weekly.
{"yearsCitations":{"type":"bar","data":{"show":true,"labels":[2019,2020,2021,2022,2023,2024],"ids":[0,0,0,0,0,0],"codes":[0,0,0,0,0,0],"imageUrls":["","","","","",""],"datasets":[{"label":"Citations number","data":[4,5,3,7,3,1],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6"],"percentage":["17.39","21.74","13.04","30.43","13.04","4.35"],"barThickness":null}]},"options":{"indexAxis":"x","maintainAspectRatio":true,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"}},"x":{"ticks":{"stepSize":1,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"}}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Citations per year","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"journals":{"type":"bar","data":{"show":true,"labels":["Cancers","PLoS ONE","Russian Chemical Bulletin","Frontiers in Oncology","Cancer Chemotherapy and Pharmacology","Journal of Experimental and Clinical Cancer Research","Nature Reviews Drug Discovery","Oncogene","Molecular Biology Reports","Cytokine and Growth Factor Reviews","Pharmacology and Therapeutics","Toxicon","Cellular and Molecular Gastroenterology and Hepatology","International Journal of Biological Macromolecules","Polymers for Advanced Technologies","Expert Review of Anticancer Therapy","Polycyclic Aromatic Compounds","Clinical Cancer Research","MedComm \u2013 Oncology","Clinical Genetics","Cancer Reports"],"ids":[22471,24963,10918,10990,17457,5741,14344,20423,2791,23916,22929,13716,13779,23035,20318,24333,15253,6723,30050,3903,28605],"codes":[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],"imageUrls":["\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/PRGhlgB4OKRltSNtT39eA6wlnOTGRap1QQ6FQHih_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/bRyGpdm98BkAUYiK1YFNpl5Z7hPu6Gd87gbIeuG3_medium.webp","\/storage\/images\/resized\/5YZtvLvkPZuc2JHOaZsjCvGSHFCuC3drUwN3YAc5_medium.webp","\/storage\/images\/resized\/5YZtvLvkPZuc2JHOaZsjCvGSHFCuC3drUwN3YAc5_medium.webp","\/storage\/images\/resized\/cfuVw6XIq2mATDNJdXiose3W8qYbkmaVSpHoP8XL_medium.webp","\/storage\/images\/resized\/bRyGpdm98BkAUYiK1YFNpl5Z7hPu6Gd87gbIeuG3_medium.webp","\/storage\/images\/resized\/bRyGpdm98BkAUYiK1YFNpl5Z7hPu6Gd87gbIeuG3_medium.webp","\/storage\/images\/resized\/bRyGpdm98BkAUYiK1YFNpl5Z7hPu6Gd87gbIeuG3_medium.webp"],"datasets":[{"label":"","data":[2,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6"],"percentage":[8.7,8.7,4.35,4.35,4.35,4.35,4.35,4.35,4.35,4.35,4.35,4.35,4.35,4.35,4.35,4.35,4.35,4.35,4.35,4.35,4.35],"barThickness":13}]},"options":{"indexAxis":"y","maintainAspectRatio":false,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"}},"x":{"ticks":{"stepSize":null,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"}}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Journals","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"publishers":{"type":"bar","data":{"show":true,"labels":["Springer Nature","Elsevier","Wiley","Multidisciplinary Digital Publishing Institute (MDPI)","Public Library of Science (PLoS)","Taylor & Francis","Frontiers Media S.A.","American Association for Cancer Research (AACR)"],"ids":[8,17,11,202,344,18,208,2286],"codes":[0,0,0,0,0,0,0,0],"imageUrls":["\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/bRyGpdm98BkAUYiK1YFNpl5Z7hPu6Gd87gbIeuG3_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/PRGhlgB4OKRltSNtT39eA6wlnOTGRap1QQ6FQHih_medium.webp","\/storage\/images\/resized\/5YZtvLvkPZuc2JHOaZsjCvGSHFCuC3drUwN3YAc5_medium.webp","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/cfuVw6XIq2mATDNJdXiose3W8qYbkmaVSpHoP8XL_medium.webp"],"datasets":[{"label":"","data":[6,5,4,2,2,2,1,1],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6"],"percentage":[26.09,21.74,17.39,8.7,8.7,8.7,4.35,4.35],"barThickness":13}]},"options":{"indexAxis":"y","maintainAspectRatio":false,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"}},"x":{"ticks":{"stepSize":null,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"}}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Publishers","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}}}
Metrics
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
MISHRA R. et al. Activating HER3 mutations in breast cancer // Oncotarget. 2018. Vol. 9. No. 45. pp. 27773-27788.
GOST all authors (up to 50)
Copy
MISHRA R., Alanazi S., Yuan L., Solomon T. C., Thaker T. M., Jura N., Garrett J. T. Activating HER3 mutations in breast cancer // Oncotarget. 2018. Vol. 9. No. 45. pp. 27773-27788.
Cite this
RIS
Copy
TY - JOUR
DO - 10.18632/oncotarget.25576
UR - https://doi.org/10.18632%2Foncotarget.25576
TI - Activating HER3 mutations in breast cancer
T2 - Oncotarget
AU - MISHRA, ROSALIN
AU - Alanazi, Samar
AU - Yuan, Long
AU - Solomon, Thomas C.
AU - Thaker, Tarjani M.
AU - Jura, Natalia
AU - Garrett, Joan T.
PY - 2018
DA - 2018/06/11 00:00:00
PB - Impact Journals
SP - 27773-27788
IS - 45
VL - 9
PMID - 29963236
SN - 1949-2553
ER -
Cite this
BibTex
Copy
@article{2018_MISHRA,
author = {ROSALIN MISHRA and Samar Alanazi and Long Yuan and Thomas C. Solomon and Tarjani M. Thaker and Natalia Jura and Joan T. Garrett},
title = {Activating HER3 mutations in breast cancer},
journal = {Oncotarget},
year = {2018},
volume = {9},
publisher = {Impact Journals},
month = {jun},
url = {https://doi.org/10.18632%2Foncotarget.25576},
number = {45},
pages = {27773--27788},
doi = {10.18632/oncotarget.25576}
}
Cite this
MLA
Copy
MISHRA, ROSALIN, et al. “Activating HER3 mutations in breast cancer.” Oncotarget, vol. 9, no. 45, Jun. 2018, pp. 27773-27788. https://doi.org/10.18632%2Foncotarget.25576.
Profiles